NICE has issued a preliminary assessment in which it recommends against public funding in England for Clinuvel’s novel drug Scenesse for the ultra-rare condition, erythropoietic protoporphyria (EPP). The company says it intends to pursue reimbursement in the coming months.
The National Institute for Health and Care Excellence (NICE) has issued a draft assessment recommending that Clinuvel’s novel drug, Scenesse (afamelanotide), for preventing phototoxicity in patients with erythropoietic protoporphyria (EPP), should not be available on the National Health Service in England.
Although clinical trial results showed the product “may be effective” and there are no other treatments available for EPP, NICE...
Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.
Industry says it is ready to work with the government on the recommendations from a major review of Australia’s health technology assessment system that covers areas such as discount rate reductions and setting up a separate budgetary allocation to temporarily subsidize access to certain drugs.
The UK will require all antibiotic manufacturers looking to apply for funding under its subscription payment model to demonstrate they are meeting waste discharge standards in a bid to reduce antimicrobial resistance.
Pharmaceutical companies should only use AI in evidence generation and reporting where there is “demonstrable value from doing so,” according to England’s health technology assessment body, NICE.
Pharmacy benefit manager sues Federal Trade Commission claiming chair Khan has orchestrated a campaign against PBMs that is not based in fact.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.
